ClinicalTrials.Veeva

Menu

Occupational and Environmental Origins of ANCA Vasculitis: Contribution of Data From the National Network for Vigilance and Prevention of Occupational Pathologies (RNV3P) (ANCAPRO)

R

Regional University Hospital Center (CHRU)

Status

Unknown

Conditions

ANCA Associated Vasculitis
Environmental Exposure
Occupational Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT05416723
ANCAPRO (29BRC22.0035)

Details and patient eligibility

About

The main objective is to identify specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified by questioning, geographical distribution of cases) from the RNV3P data.

The secondary objectives are as follows:

  • Description of cases of ANCA vasculitis seen in French occupational pathology consultation centres:

    • reasons for consultation,
    • occupational and environmental etiologies described
    • occupational situations responsible
    • aptitude notices
    • recognition as an occupational disease
  • Identification of specific risk factors for ANCA vasculitis of occupational and/or environmental origin (exposures identified on questioning, geographical distribution of cases).

  • For occupational and non-occupational cases of ANCA vasculitis: identification of difficulties encountered by patients at work and proposed work adaptations.

  • Estimation of the number of applications for recognition of disabled worker status made within this patient group.

  • Identification of clinical severity and autoimmune profiles of ANCA vasculitis of occupational and/or environmental origin.

Enrollment

302 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with ANCA vasculitis defined according to the International Classification of Diseases (ICD-10), i.e. M 308, M 31, N 057 and L 95, or mentioned as the reason for consultation in the text mining summary.
  • Seen in consultation in the occupational disease consultation centres belonging to the RNV3P
  • No opposition

Exclusion criteria

  • Refusal to participate

Trial contacts and locations

11

Loading...

Central trial contact

Brice LODDE; Greta GOURIER

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems